Talquetamab in multiple myeloma.

Abstract

Initial results of the Phase 1 trial of talquetamab, a bispecific antibody targeting GPRC5D and CD3, were reported in December of 2022 for the treatment of relapsed or refractory multiple myeloma in the fourth line or later setting. It demonstrated a similar efficacy profile and durability of response to teclistamab, the first bispecific antibody therapy to be approved in multiple myeloma. Additionally, it has less infections than teclistamab but demonstrates unique class specific side effects including skin, oral, and nail-related adverse events. Despite this, it is still a highly efficacious and well-tolerated therapy that will add to the armamentarium of therapeutics against heavily pretreated multiple myeloma.

• Authors: Lawrence Liu, Amrita Krishnan
• Journal: Haematologica (Haematologica) (Oct 19 2023) ISSN: 1592-8721 [Electronic] Italy
• PMID: 37855056 (Publication Type: Journal Article)